NCT04617093 - Post-Market Study of Low-flow ECCO2R Using PrismaLung+ | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

December 5, 2023

Study Completion Date

January 10, 2024

Conditions

Mild to Moderate Acute Respiratory Distress Syndrome

Interventions

DEVICE

PrismaLung+

Overall, up to 60 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as standalone therapy and another minimum of approximately 15 patients will receive ECCO2R using PrismaLung+ in combination with CRRT.

Trial Locations (10)

13354

Investigational Site, Marseille

25030

Investigational Site, Besançon

34295

Investigational Site, Montpellier

54511

Investigational Site, Vandœuvre-lès-Nancy

59037

Investigational Site, Lille

67098

Investigational Site, Strasbourg

75013

Investigational Site, Paris

75651

Investigational Site, Paris

92700

Investigational Site, Colombes

94010

Investigational Site, Créteil

All Listed Sponsors

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Vantive Health LLC

INDUSTRY